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Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age,
disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-
directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941
patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91
centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was
restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care
unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to
untreated (p < 0.001). Untreated patients had a lower risk of death (HR= 0.54, 95% CI:0.41–0.72). The risk of death was higher for
older patients and those suffering from cardiac failure (HR= 1.03, 95% CI:1.02–1.04; HR= 1.79, 95% CI:1.04–3.07, respectively). Age,
CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival
than those on treatment or recently treated.
Leukemia; https://doi.org/10.1038/s41375-021-01450-8
INTRODUCTION
The Coronavirus disease 2019 (COVID-19) has cost the lives of
more than 3 million people worldwide, since the first cases were
reported in December 2019 in Wuhan, China [1]. While the severity
of the disease can vary greatly between infected individuals, older
age, and specific comorbidities confer a worse prognosis. Obesity,
diabetes mellitus, cardiovascular, respiratory diseases, and cancer
are associated with poor outcome [2, 3].
Patients with hematological malignancies often experience
severe disease and have high case fatality (CFR) and mortality
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rates. A meta-analysis of 3240 adult patients with a hematological
malignancy reported a risk of death of 34% [4]. Moreover, in a
study of 740 patients with hematological malignancies from
Turkey the CFR was significantly higher when compared with age,
sex, and comorbidity-matched controls (13.8% vs 6.8%) [5]. In a
similar patient group from Italy, Passamonti et al. reported a
standardized mortality ratio of 2.04 (95% CI 1.77–2.34) compared
with the Italian general population with COVID-19 [6].
Chronic lymphocytic leukemia (CLL) is the most frequent adult
hematological malignancy in the West, affecting particularly the
elderly, with a median age at diagnosis of 72 years [7]. CLL is
characterized by an impaired immune capacity due to a profound
immune dysregulation reflected by hypogammaglobulinemia,
qualitative and quantitative B- and T-cell defects, CD4+ lympho-
penia, innate immune dysfunction, and neutropenia [8]. Antileu-
kemic treatments can further weaken the immune response to
common pathogens, rendering patients more susceptible to
infections [9]. CLL immune defects may hinder the host from
effectively controlling SARS-CoV-2 replication. Conversely, while
patients with CLL might struggle to eliminate the virus, they may
be less prone to a cytokine-induced inflammatory hyperactivation
that can lead to acute respiratory distress syndrome, multiorgan
damage, and death [10].
Early in the pandemic, reports from hospitalized patients
showed that those with hematological malignancies were more
susceptible to severe infection from SARS-CoV-2 and had higher
CFR compared to the general population [11, 12]. In those studies,
CLL was underrepresented and the impact of specific antileukemic
treatments was not assessed. In a COVID-19 and CLL-specific
cohort of 46 Italian patients, the Campus CLL group reported a
CFR of 30.4% [13]. Following this report, ERIC, the European
Research Initiative on CLL, and Campus CLL reported data from
190 patients [14]. Among hospitalized patients, the CFR was
32.5%. Age and number of comorbidities did not impact on
overall survival (OS); patients on recent or ongoing treatment
were more likely to have milder COVID-19 compared to untreated
patients; finally, patients treated with the Bruton’s tyrosine kinase
inhibitor (BTKi) ibrutinib were less likely to be hospitalized,
prompting us to suggest a possible protective effect.
Mato et al. reported the outcomes of 198 patients with COVID-
19 and CLL mainly from the USA [15]. The overall CFR was 33%. No
difference was observed between treated and untreated patients
with regard to infection severity and mortality. Advanced age and
specific comorbidities conferred a worse prognosis. BTKi did not
show a protective effect; however, in most cases, they were held
during the infection.
The ERIC and US cohorts were also analyzed together with a
Spanish cohort in a joint effort. The CFR was 30–34%. Age was the
only risk factor of fatality in both cohorts, while the effect of CLL
treatment on OS was inconsistent across cohorts. None of the CLL-
directed treatments affected OS [16].
As SARS-CoV-2 is still surging across the globe, we significantly
expanded our retrospective international multicenter cohort of
patients with CLL and COVID-19. We aimed at reassessing the risk
factors for COVID-19-related fatality and elucidate further the
impact of CLL-directed treatments.
METHODS
Data collection
This is a retrospective international multicenter study of the ERIC and the
Campus CLL. It represents a continuation of a previous study conducted
during the first wave of the pandemic [14]. Investigators at each center
updated the information of their previous cases and added any new
patients with COVID-19 and CLL/small lymphocytic lymphoma (SLL) or
high-count CLL-like monoclonal B-cell lymphocytosis (MBL), a pre-CLL
condition, also characterized by inherent immune compromise [17]. The
establishment of CLL diagnosis, treatment decisions, review of medical
history, and assessment of patient status were performed by the local
teams following international guidelines [18]. The study was approved by
the institutional ethics committees and data were processed and treated
lawfully and fairly in a transparent manner that ensured appropriate
security of the personal data, abiding by the General Data Protection
Regulation. Informed consent was obtained from all patients that survived
the infection. Data collection took place between March 28 and May 22,
2020 (first study) and between December 01, 2020, and March 16, 2021
(current study). Investigators reported all their patients with CLL or related
conditions (SLL or MBL) who were diagnosed with COVID-19 from the
beginning of the pandemic until the completion of the collection.
Ninety-one institutions participated in the study providing information
for a total of 1009 cases. After excluding cases with uncertain diagnosis
(‘atypical CLL’) and those without a qRT-PCR positive test for SARS-CoV-2,
we resulted in 941 patients to be studied, 190 of whom were included in
the first study. The full list of participating countries is reported in
Supplemental Table 1.
Data extracted from the medical records included: baseline demo-
graphics; date of CLL diagnosis; IGHV gene somatic hypermutation status;
cytogenetic status for chromosomes 11q, 13q 17p, and 12 determined by
fluorescence in situ hybridization (at last assessment); TP53 gene mutation
status assessed by Sanger sequencing or next-generation sequencing (at
last assessment); CLL treatment status; presence, number, and type of
comorbidities, date of COVID-19, COVID-19 symptoms, COVID-19 manage-
ment, treatment, complications, and outcome.
OS was defined as the time from suspected COVID-19 to death or last
follow-up date.
In keeping with international practice, patients were deemed to have
COVID-19 if a qRT-PCR assay test from a throat or nose swab was positive
for SARS-CoV-2.
Severe COVID-19 was defined as hospitalization and need of oxygen or
admission into an intensive care unit; nonsevere/mild COVID-19 was
defined as confinement at home or hospitalization without need of
oxygen.
Patients diagnosed with COVID-19 from the start of the pandemic until
June 30, 2020, were considered to belong to the 1st wave of SARS-CoV-2,
while patients diagnosed from July 1st until the completion of data
collection were designated to the 2nd wave. The cut-off was decided
based on the disposition of cases in our cohort (Supplemental Fig. 1).
Statistical analysis
Median (IQR) is used to describe numeric variables while frequencies and
percentages are used for categorical. Both univariate and multivariate
analyses were carried out, having COVID-19 disease severity, CFR, or OS as
outcomes. As potential risk factors, we examined clinico-biological
characteristics (age, comorbidities, gender, IGHV gene somatic hypermuta-
tion status, TP53 aberrations), COVID-19 disease severity (where appro-
priate), CLL treatment status (at the time of COVID-19 and in the last
12 months), type of CLL treatment (at the time of COVID-19 and in the last
12 months), and measures taken for the management of COVID-19
(continued as planned, replaced with other, or stopped the treatment).
Also, we compared CFR between the two waves. To this end, to reduce the
impact of confounding factors, we firstly tested for differences of the
above-mentioned risk factors between the two waves. The statistical
analyses were carried out in either all patients or subsets of the dataset
(only severe, only patients receiving BTKi at the time of COVID-19). In the
analyses for CFR, patients who were still under medical care were
excluded. The significance level was set to 5%. In post-hoc comparisons,
the correction of Bonferroni was used.
For COVID-19 disease severity and CFR, χ2 test or Fisher’s exact test
(when necessary) were used for univariate analyses, while logistic
regression was used for the multivariate. When necessary, we performed
bias reduction techniques to the logistic model estimates by adjusting
Firth’s logistic regression. Furthermore, for the comparison of CFR between
the two waves, age was used as a confounder, since statistically significant
older patients were identified in the first wave. For the comparisons of the
numeric risk factors between the two waves, independent samples t-tests
(Student’s or Welch’s) were conducted. The homogeneity of variance
between the two groups was examined through Levene’s test. For the
categorical risk factors, χ2 test or Fisher’s exact test were used.
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For OS, the log-rank test was used for the univariate analyses, and Cox
regression was conducted for the multivariate.
For the multivariate analyses, we performed a two-level variable
selection approach. At first, we obtained the statistically significant risk
factors through univariate analyses and used them as risk factors for a
multivariate model. We further explored the multivariate model by
performing backward elimination using p value.
All statistical analyses were conducted using R 4.0.4. We used brglm
package [19] for Firth’s logistic regression, survival [20], and survminer
packages [21] for survival analysis and ggplot2 package [22] for data
visualization (Kaplan–Meier curves and the line-plot).
RESULTS
Patient characteristics
We included 941 patients with a median age of 69 years (IQR
61–77) at the time of SARS-CoV-2 infection. Most patients were
diagnosed with CLL (887, 94.3%), while 38 and 16 patients were
diagnosed with SLL and MBL, respectively. The majority (628/941,
66.7%) were male with a median number of comorbidities of 2.
Baseline patient characteristics are shown in Table 1.
Regarding CLL history, 394 patients (41.9%) had never received
treatment for CLL, while 547 (58.1%) had been treated with at
least one line of treatment. Amongst treated patients, 320 (34%)
were on treatment at the time of SARS-CoV-2 infection. The most
common treatment category at the time of COVID-19 was BTKi
monotherapy (56.3%), followed by venetoclax monotherapy
(10.7%) and chemoimmunotherapy (9.1%). Detailed information
about CLL-directed therapy is given in Table 2.
COVID-19 manifestations and management
The majority of patients (887/941, 94.3%) were symptomatic at the
time of documented SARS-COV-2 infection. Fever was the most
common COVID-19 related symptom (Supplemental Table 2).
In total, 237/941 (25.3%) patients were confined at home, while
695/941 (74.7%) patients were admitted to the hospital. Of the
hospitalized patients, 177 (25.5%) were admitted to the ICU, 440
(63.3%) needed oxygen supplementation outside the ICU, and 78
(11.2%) were hospitalized without need of oxygen (Table 3).
Most hospitalized patients received pharmacologic treatment
for COVID-19. Corticosteroids were the most commonly used
treatment. In most cases (212/320, 66.2%), CLL-directed treatment
was stopped during COVID-19 infection (Table 2). Signs of
pneumonia were detected in 659/874 patients (75.4%). Forty-
eight patients (6.2%) developed venous thromboembolism (40/48
pulmonary embolism) (Table 3).
COVID-19 severity
Age, CIRS score, hypogammaglobulinemia, and specific comorbid-
ities (COPD, coronary artery disease, diabetes, chronic renal
disease) were identified as risk factors of severity in the univariate
analyses. In the multivariate model, age (OR= 1.04; 95% CI:
1.02–1.06; p < 0.001), hypogammaglobulinemia (OR= 1.69; 95%
CI: 1.20–2.38; p= 0.002), and coronary artery disease (OR= 2.83;
95% CI: 1.37–6.61; p= 0.009) remained statistically significant
(Supplemental Table 3).
CLL treatment did not affect the severity of COVID-19. No
difference was found in terms of severity between patients
receiving BTKi at the time of COVID-19 versus untreated patients.
Among 179 patients receiving BTKi at the time of COVID-19, age
(OR= 1.04; 95% CI: 1.01–1.08; p= 0.017) and hypogammaglobu-
linemia (OR= 2.21; 95% CI: 1.13–4.36; p= 0.021) remained
statistically significant predictors in the multivariate analysis
(Supplemental Table 4).
Overall survival and risk factors of fatality
In total, the CFR for all patients was 27.3% (257/941) (Supple-
mental Fig. 2). In 647 patients (69%) the infection resolved, 34
were under medical care at the time of data collection and in 3 the
infection outcome was missing (Table 3). The vast majority of
deaths occurred in patients with severe COVID-19 (236/617). Only
15 deaths occurred amongst 315 patients with nonsevere COVID-
19 (CFR: 4.8%).
The baseline characteristics were similar between the two
waves, except for age (p < 0.001) (Supplementary Tables 5, 6, and
7). The median age in the first wave was 71 years (with 39.9%
older than 75 years) while in the second wave it was 68 years (with
27% older than 75 years). No difference in CFR was found between
the first and second wave of COVID-19 in both all patients or only
in patients with severe COVID-19, even after controlling for age (p
= 0.78; p= 0.16, respectively) (Supplemental Tables 5 and 6).
In order to avoid collection bias, we restricted the analysis for
both infection outcome and OS to patients with severe COVID-19
infection. We also excluded patients who were still under medical
care and those missing information about the infection outcome.
The CFR for patients with severe COVID-19 was 38.4%
(Supplemental Fig. 3). Through univariate analyses, age, unmu-
tated IGHV gene somatic hypermutation status, specific comor-
bidities, and treatment status were observed as statistically
significant risk factors for mortality. Age (OR= 1.04; 95% CI:
1.02–1.06; p < 0.001), cardiac failure (OR= 3.82; 95% CI: 1.31–13.94;
p= 0.023) and treatment in the last 12 months (OR= 2.13; 95% CI:
1.44–3.20; p < 0.001) remained statistically significant in
Table 1. Patient Characteristics.
Patient characteristics Results Missing
Age at COVID-19, years
(median, IQR)
69 (61–77) 0 (0%)
Gender Female 313 (33.3%) 0 (0%)
Male 628 (66.7%)
Diagnosis CLL 887 (94.3%)
MBL 16 (1.7%)
SLL 38 (4%)
Obesity (BMI > 30) 151 (17.3%) 70 (7.4%)





352 (49.5%) 230 (24.4%)
CIRS score (median, range) 4 (0–32) 76 (8.1%)
N of comorbidities
(median, range)
2 (0–11) 0 (0%)
Other respiratory 61 (6.5%) 4 (0.4%)
Asthma 21 (2.2%) 4 (0.4%)
COPD 61 (6.5%) 4 (0.4%)
Cardiac Failure 30 (3.2%) 4 (0.4%)
Arrythmias 87 (9.3%) 4 (0.4%)
Coronary artery disease 94 (10%) 4 (0.4%)
Other cardiovascular 83 (8.9%) 4 (0.4%)
Hypertension 440 (47%) 4 (0.4%)
Diabetes 173 (18.5%) 4 (0.4%)
Chronic renal disease 51 (5.4%) 4 (0.4%)
Other hematological
malignancies
10 (1.1%) 4 (0.4%)
Other non-hematological
malignancies (excluding skin)
75 (8%) 4 (0.4%)
IQR interquartile range, CIRS cumulative illness rating scale, COPD chronic
obstructive pulmonary disease, CLL chronic lymphocytic leukemia, SLL
small lymphocytic lymphoma, MBL monoclonal B lymphocytosis.
T. Chatzikonstantinou et al.
3
Leukemia
Table 2. CLL-directed treatment.
Treatment Category Number Percentage Missing
CLL treatment status Treated 547 58.1% 0 (0%)
Untreated 394 41.9%
Treated status in last 12 months Treated 432 46% 2 (0.2%)
Untreated 507 54%
Treatment status for CLL at the time of COVID-19 Treated 320 34% 1 (0.1%)
Untreated 620 66%
Management of CLL treatment Continued as planned 104 32.7% (0.6%)
Replaced with other 2 0.6%
Stopped 212 66.7%





Treatment at the time of COVID-19 BTKi 179 56.3% 2 (0.6%)
Venetoclax 34 10.7%
Venetoclax +Anti-CD20 17 5.3%
PI3K inhibitors 10 3.1%




BTKi + Venetoclax 7 2.2%
BTKi + Venetoclax + Anti-CD20 2 0.6%
Steroids only 7 2.2%
PI3K Phosphatidylinositol-3 kinase, BTKi Bruton’s tyrosine kinase inhibitor.




Intensive care 177 19% 9 (1%)
Hospitalization with need of oxygen 440 47.2%
Hospitalization without need of oxygen 78 8.4%
Confinement at home only 237 25.4%
Disease severity Severe 617 66.2% 9 (1%)
Nonsevere 315 33.8%
Hospitalization Hospitalization 695 74.6% 9 (1%)
Home 237 25.4%
Antiviral 266 35.7% 195 (20.7%)
Hydroxycloroquine or similar 203 27.1% 192 (20.4%)
Azithromycin 265 35.9% 202 (21.5%)
Steroids 514 61.3% 103 (10.9%)
Anti-IL6/IL6R 84 11.4% 204 (21.7%)
Convalescent/ Hyperimmune plasma 44 7.5% 351 (37.3%)
Pneumonia 659 75.4% 67 (7.1%)
Complications of COVID-19
infection
DIC 7 0.9% 167 (17.7%)
VTE 48 6.2%
PE (only for 48 with VTE) 40 87% 2 (4.2%)
Infection outcome Resolution 647 69% 3 (0.3%)
Still under medical care 34 3.6%
Death 257 27.4%
DIC disseminated intravascular coagulation, VTE venous thromboembolism, PE pulmonary embolism.
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Table 4. Risk factors of infection outcome for patients with severe COVID-19 (n= 594).
Risk factor Categories Infection outcome RR p value
Resolution Death
Age ≥ 65 240 (57.1%) 180 (42.9%) 1.33 0.02
<65 118 (67.8%) 56 (32.2%)
Age ≥75 104 (47.5%) 115 (52.5%) 1.63 <0.001
<75 254 (67.7%) 121 (32.3%)
Gender Male 117 (60.9%) 75 (39.1%) 0.98 0.89
Female 241 (60%) 161 (40%)
IGHV gene somatic hypermutation status Mutateda 91 (66.4%) 46 (33.6%) 0.70 0.017
Unmutatedb 91 (52.3%) 83 (47.7%)
del(13q) (last assessment) Negative 113(56.5%) 87 (43.5%) 1.14 0.37
Positive 103 (61.7%) 64 (38.3%)
del(11q) (last assessment) Negative 185 (60.3%) 122 (39.7%) 0.83 0.3
Positive 34 (52.3%) 31 (47.7%)
trisomy 12 (last assessment) Negative 176 (60.5%) 115 (39.5%) 0.87 0.45
Positive 36 (54.5%) 30 (45.5%)
del(17p) (last assessment) Negative 206 (59.7%) 139 (40.3%) 0.75 0.09
Positive 23 (46%) 27 (54%)
TP53 mutation status Mutated 18 (48.6%) 19 (51.4%) 1.23 0.37
Unmutated 137 (58.1%) 99 (41.9%)
del(17p) positive and/or TP53 mutation Yes 33 (50%) 33 (50%) 1.2 0.29
No 130 (58.3%) 93 (41.7%)
CIRS score ≤6 242 (65.4%) 128 (34.6%) 0.68 <0.001
>6 87 (49.4%) 89 (50.6%)
Other respiratory Yes 24 (60%) 16 (40%) 1 >0.99
No 332 (60.1%) 220 (39.9%)
Asthma Yes 10 (66.7%) 5 (33.3%) 0.83 0.8
No 346 (60%) 231 (40%)
COPD Yes 22 (47.8%) 24 (52.2%) 1.35 0.11
No 334 (61.2%) 212 (38.8%)
Cardiac Failure Yes 5 (25%) 15 (75%) 1.94 0.002
No 351 (61.4%) 221 (38.6%)
Arrythmias Yes 33 (57.9%) 24 (42.1%) 1.06 0.83
No 323(60.4%) 212(39.6)
Coronary artery disease Yes 32 (44.4%) 40 (55.6%) 1.47 0.006
No 324 (62.3%) 196 (37.7%)
Other cardiovascular Yes 32 (54.2%) 27 (45.8%) 1.17 0.4
No 324 (60.8%) 209 (39.2%)
Hypertension Yes 167 (56.8%) 127 (43.2%) 1.18 0.12
No 189 (63.4%) 109 (36.6%)
Diabetes Yes 80 (64%) 45 (36%) 0.88 0.37
No 276 (59.1%) 191 (40.9%)
Chronic renal disease Yes 15 (40.5%) 22 (59.5%) 1.54 0.019
No 341 (61.4%) 214 (38.6%)
Other hematological malignancies Yes 5 (55.6%) 4 (44.4%) 1.16 0.75
No 351 (60.2%) 232 (39.8%)
Other non-hematological malignancies (excluding skin) Yes 27 (61.4%) 17 (38.6%) 0.97 0.99
No 329 (60%) 219 (40%)
Obesity (BMI>30) Yes 57 (61.3%) 36 (38.7%) 0.99 >0.99
No 280 (61.1%) 178 (38.9%)
Smoking Current smoker 25 (59.5%) 17 (40.5%) 0.58
Ex-smoker 82 (57.7%) 60 (42.3%)
Never 212 (62.7%) 126 (37.3%)
Hypogammaglobulinemia (IgG <550mg/dL) Present 133 (55.6%) 106 (44.4%) 1.33 0.017
Absent 146 (67%) 72 (33%)
CLL treatment status Treated 168 (49.9%) 169 (50.1%) 1.92 <0.001
Untreated 190 (73.9%) 67 (26.1%)
CLL treatment status at the time of COVID-19 Treated 94 (47.7%) 103 (52.3%) 1.56 <0.001
Untreated 263 (66.4%) 133 (33.6%)
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multivariate analysis (Table 4). We performed the same analysis
including only the patients with severe COVID-19 that were
reported from centers that participated in both studies. In the
multivariate analysis, age and CLL treatment status remained
statistically significant risk factors (Supplemental Table 8).
Univariate and multivariate analyses of risk factors of OS are
outlined in Table 5. Older age (HR= 1.03; 95% CI: 1.02–1.04; p <
0.001), cardiac failure (HR= 1.79; 95% CI: 1.04–3.07; p= 0.035) and
treatment status (HR= 0.54; 95% CI: 0.41–0.72; p < 0.001)
appeared as statistically significant risk factors of OS in the
multivariate analysis.
Comparison of OS between treated and untreated patients is
depicted graphically in Fig. 1.
CLL-directed treatment and COVID-19 outcome
We assessed the impact of specific treatment categories on
COVID-19 outcome. Initially, we compared patients receiving BTKi
at the time of SARS-COV-2 infection (n= 169) with patients
receiving venetoclax at the same time (n= 31) and patients who
had received chemoimmunotherapy in the last 12 months (n=
85). Then, in a second comparison, we kept the first two categories
and replaced the third one with patients who had received any
anti-CD20-based therapy (alone or in combination) in the last
12 months (n= 128). No statistically significant difference
between the groups was noted in either analysis. Nonetheless,
treated patients (in any treatment category) had a worse OS when
compared to the untreated ones (p < 0.001) (Fig. 2 and Supple-
mental Fig. 4).
One hundred and ten patients with severe COVID-19 were being
treated with BTKi monotherapy at the time of COVID-19. Thirty
patients continued the BTKi treatment, while in 78 cases physicians
chose to hold the drug. Patients who continued BTKi treatment did
not have a statistically better outcome than those who discon-
tinued the treatment (p= 0.08), while both groups had a worse
outcome compared with untreated patients (p < 0.001) (Table 6).
DISCUSSION
We here present the largest cohort published to date of patients
with CLL and COVID-19. In this homogeneous disease-specific
series, age, history of cardiac failure, and CLL treatment were the
main risk factors for a dismal outcome.
In our study, the finding that older patients with CLL often have
severe disease, higher CFRs, and lower survival time is in line with
data derived from the general population, where COVID-19-
related fatality and time to death positively correlated with age
[3, 23, 24]. Relevant to add, similar results have been reported in a
US study by Mato et al. showing that patients with CLL older than
75 years had a worse OS [15]. Older patients were also more likely
to die in our first cohort, albeit without reaching statistical
signifigance, which can be attributed to the smaller sample.
In our original cohort including patients from the first wave of
SARS-CoV-2 [14], higher CIRS score and certain comorbidities were
linked with increased mortality, whereas in this updated cohort
only cardiac failure remained a statistically significant comorbidity
in the multivariate analysis. OS was unaffected by diabetes,
respiratory diseases, and obesity, variables conferring a worse
prognosis in COVID-19 patients when analyzed in the general
population [2, 3]. Nonetheless, some caution is warranted
regarding the precise impact of specific comorbidities on
COVID-19 outcome in patients with CLL since information on
their severity was not collected systematically.
In this updated cohort, patients treated for CLL had a worse OS
than untreated patients, while in both the report by Mato et al
(198 patients, end point: outcome) and our previous report (190
patients, end point: severity), no difference was found between
treated and untreated patients, probably due to the lower number
of cases [14, 15]. Of note, when our previous cohort was combined
with the Spanish cohort (281 patients), untreated patients had
better OS than treated ones [16]. Thus, these apparent discre-
pancies may simply reflect the larger sample of our current
analysis that allowed to identify a difference between the
Table 4 continued
Risk factor Categories Infection outcome RR p value
Resolution Death
Treated in last 12 months Yes 132 (48.4%) 141 (51.6%) 1.42 0.002
No 116 (63.7%) 66 (36.3%)
Antiviral Yes 140 (63.6%) 80 (36.4%) 1.07 0.65
No 177 (66%) 91 (34%)
Hydroxycloroquine or similar Yes 116 (67.1%) 57 (32.9%) 0.92 0.61
No 200 (64.3%) 111 (35.7%)
Azithromycin Yes 125 (69.4%) 55 (30.6%) 0.84 0.23
No 187 (63.6%) 107 (36.4%)
Steroids Yes 264 (63%) 155 (37%) 1.04 0.88
No 67 (64.4%) 37 (35.6%)
Anti-IL6/IL6R Yes 55 (66.3%) 28 (33.7%) 0.95 0.87
NO 257(64.6%) 141 (35.4%)




Risk factor OR 95% CI p value
Age (years) 1.04 1.02–1.06 <0.001
Cardiac failure (YES vs NO) 3.82 1.31–13.94 0.023
Treated in last 12 months (Treated vs Untreated) 2.13 1.44–3.20 <0.001
IGHV immunoglobulin heavy variable, CIRS cumulative illness rating scale, COPD chronic obstructive pulmonary disease, RR relative risk of death.
aMutated: < 98% germline identity.
bUnmutated: ≥98% germline identity.
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untreated and the treated, likely more immunosuppressed,
patients.
Untreated patients had a better outcome also when compared
separately with patients in different treatment categories (BTKi,
venetoclax, chemoimmunotherapy, or anti-CD20 containing regi-
mens). Patients who continued BTKi treatment during COVID-19
infection did not appear to fare worse than those who stopped
the drug with a potential benefit albeit not statistically significant,
suggesting that BTKi continuation definitely is not harming
patients and may potentially benefit them by preventing
respiratory failure and death or by keeping CLL under control
[25]. This is in line with the current recommendations indicating
no need to hold BTKi at the time of a confirmed SARS-CoV-2
infection [26].
Patients treated with anti-CD20 antibodies, alone or in
combination, had worse OS than untreated patients. This finding
suggests that such treatment likely renders patients with CLL
more susceptible to succumb to COVID-19 infection. That said, the
small number of patients treated with the combination of anti-
CD20 antibodies with novel agents in the present cohort hinders
firm conclusions from being drawn regarding its precise impact on
COVID-19 outcome.
The CFR in the entire cohort was 27.4% and increased to 38.4%
among patients with severe COVID-19. This indicates a remarkable
consistency among different studies in patients with CLL and
COVID-19 as well as in the different waves of the pandemic,
confirming the unabated aggressiveness of the disease with time
[14–16]. In the general population, the CFR in hospitalized patients
appears lower compared to our cohort: indicatively, a meta-
analysis of COVID-19 patients found a fatality rate of 17.1% and
40.5% for hospitalized and critically ill patients, respectively [27].
Similarly, in-hospital mortality of patients older than 75 years in a
US study was 20.5% [28]. Nevertheless, the caveats of cross-study
comparisons, the retrospective nature of our cohort, and the lack
of a control group hinder any generalization about the true impact
of CLL in COVID-19-related mortality.
In the updated cohort, CLL-directed treatment was associated
with a worse outcome. However, it had no impact on COVID-19
severity in either the orginal or the updated cohort. We suspect
that investigators were more likely to be informed about patients
on CLL-specific treatment with mild COVID-19 symptoms than
untreated patients, since the former were followed up more
closely and probably sought immediate guidance: thus, we may
have missed more asymptomatic untreated patients.
Dexamethasone and tocilizumab remain the only treatments
that showed a mortality benefit in patients with COVID-19 [29, 30].
The impact of COVID-19 treatments in our cohort was not among
the objectives, with information on the administered treatment for
COVID-19 missing at least in part. Nonetheless, we observed that
different types of therapies against COVID-19 did not affect
the CFR.
We acknowledge certain limitations in our study. As already
mentioned, hospitalized and/or symptomatic patients were more
likely to be captured in our cohort, while we probably missed
some asymptomatic or mildly symptomatic patients who avoided
undergoing testing and/or contacting their physician, especially
during the first wave, when COVID-19 testing was not the rule. To
avoid the caveats of a retrospective study and the lack of a control
group in overestimating the mortality, we restricted the analysis to
patients with severe disease and avoided broad generalizations
about prevalence, morbidity, and mortality. Taking into account
the multicenter, international design of the study, some hetero-
geneity in our patient population is to be expected as we included
patients from different countries, diagnosed with COVID-19 during
different waves of the pandemic and managed differently. Along
this line, mirroring the course of the pandemic, some countries
like Italy and Spain were overrepresented in the first wave, while
the second wave featured more patients from other countries
(e.g., Czech Republic and Greece). Finally, we recognize that
differences in the quality of health care and weather could
influence our results. Indeed, only a small number of cases were
diagnosed during the summer and none of the patients in our
cohort was vaccinated for SARS-CoV-2. In addition, the lack of any
difference in CFRs between the two waves illustrates that CLL and
treatment-related immunosuppression may overshadow other risk
factors of outcome.
Taken together, our findings suggest that in patients with CLL
and COVID-19, older age confers a worse prognosis, with
increased mortality. Untreated patients had a better chance of
survival than those on treatment or recently treated.
Table 5. Risk factors of OS.
Risk factor p value
Age (≥65 vs <65) 0.01
Age (≥75 vs <75) <0.001
Gender (Male vs Female) 0.56
IGHV gene somatic hypermutation status (unmutateda vs
mutatedb)
0.01
del(13q) (last assessment) (positive vs negative) 0.46
del(11q) (last assessment) (positive vs negative) 0.33
trisomy 12 (last assessment) (positive vs negative) 0.59
del(17p) (last assessment) (positive vs negative) 0.02
TP53 mutation status (unmutated vs mutated) 0.18
del(17p) positive and/or TP53 mutation (yes vs no) 0.1
CIRS score (> 6 vs ≤6) <0.001
Other respiratory (YES vs NO) 0.82
Asthma (yes vs no) 0.49
COPD (yes vs no) 0.12
Cardiac Failure (yes vs no) <0.001
Arrythmias (yes vs no) 0.38
Coronary artery disease (yes vs no) 0.06
Other cardiovascular (yes vs no) 0.16
Hypertension (yes vs no) 0.1
Diabetes (yes vs no) 0.52
Chronic renal disease (yes vs no) 0.02
Other hematological malignancies (yes vs no) 0.91
Other non-hematological malignancies (yes vs no) 0.87
Obesity (BMI>30) (yes vs no) 0.98
Smoking 0.8
Hypogammaglobulinemia (IgG <550mg/dL) (present vs
absent)
0.08
CLL treatment status (untreated vs treated) <0.001
CLL treatment during COVID-19 (treated vs untreated) <0.001
Treated in last 12 months (treated vs untreated) 0.01
Multivariate analysis
Risk factor HR 95% CI
Age (years) 1.03 1.02–1.04 <0.001
Cardiac failure (yes vs no) 1.79 1.04–3.07 0.04
CLL treatment status (untreated vs
treated)
0.54 0.41–0.72 <0.001
IGHV immunoglobulin heavy variable, CIRS cumulative illness rating scale,
COPD chronic obstructive pulmonary disease.
aUnmutated: ≥98% germline identity.
bMutated: <98% germline identity.




All data created during this study are included in the manuscript and supporting
material. The code for biostatistical analysis is available in the following GitHub
repository: https://github.com/gkarakatsoulis/COVID-19-in-CLL-patients.
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